Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Ascending Doses of AZ-010 and Crossover Comparison With IV Granisetron in Healthy Volunteers
NCT04200092Phase 1Completed
- Sponsor
- NovaPneuma
- Start
- Nov 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Staccato Granisetron in Nausea and Vomiting (6 arms), sponsored by NovaPneuma. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 3 days, Measurement of Granisetron Exposure in Plasma at 3 days and 2 more. Started Nov 2019; status: completed.
02
Drugs
Staccato Granisetron
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NCT04200092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200092.